Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect on Pharmacokinetics of TQB3454 in Healthy Adults
NCT06139367Phase 1Not yet recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Nov 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of TQB3454 in cholangiocarcinoma (2 arms), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Peak concentration at 330 hours, Area under the time-concentration curve from 0 to t hours at 330 hours and 5 more. Planned start Nov 2023; status: not yet recruiting.
02
Drugs
TQB3454
03
Conditions
cholangiocarcinoma
Beyond the preview
Go deeper on NCT06139367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06139367.